These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 2501110

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
    Lemay A, Maheux R, Jean C, Faure N.
    Prog Clin Biol Res; 1986; 225():157-73. PubMed ID: 3097663
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
    Schindler AE, Bühler K, Mettler L, Fuchs U, Cirkel U, Ochs H, Schweppe KW, Koch R.
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Androgens and other hormones in buserelin therapy].
    Fuchs U, Zwirner M.
    Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
    [Abstract] [Full Text] [Related]

  • 8. Treatment of endometriosis with gonadotropin releasing hormone agonist (buserelin).
    Sirimongkolkasem R, Rojanasakul A, Chailurkit LO.
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():37-41. PubMed ID: 2112582
    [Abstract] [Full Text] [Related]

  • 9. [Continuous subcutaneous infusion of GnRH agonist: effective dosage in the treatment of endometriosis and its influence on the ovarian response to human menopausal gonadotropin].
    Masaoka K, Kitazawa M, Watanabe H, Kumasaka T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):729-36. PubMed ID: 2504848
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of endometriosis. Evaluation of preoperative therapy with danazol, gestrinone and buserelin (nasal spray and implant)].
    Nisolle M, Clerckx F, Casanas-Roux F, Gillerot S, Bourgonjon D, Donnez J.
    J Gynecol Obstet Biol Reprod (Paris); 1990 Jun; 19(6):759-63. PubMed ID: 2124231
    [Abstract] [Full Text] [Related]

  • 11. Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase.
    Lemay A, Sandow J, Bureau M, Maheux R, Fontaine JY, Mérat P.
    Fertil Steril; 1988 Mar; 49(3):410-7. PubMed ID: 3125068
    [Abstract] [Full Text] [Related]

  • 12. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study.
    Dmowski WP, Radwanska E, Binor Z, Tummon I, Pepping P.
    Fertil Steril; 1989 Mar; 51(3):395-400. PubMed ID: 2493400
    [Abstract] [Full Text] [Related]

  • 13. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
    Fraser HM, Haining R, Cowen GM, Sandow J, Smith KB, Smith SK.
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis.
    Ohtsuka S, Terakawa N, Shimizu I, Sakata M, Mizutani T, Miyake A, Tanizawa O, Aono T.
    Endocrinol Jpn; 1989 Aug; 36(4):611-9. PubMed ID: 2510993
    [Abstract] [Full Text] [Related]

  • 16. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N.
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [Abstract] [Full Text] [Related]

  • 17. An implant of a gonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3-5 months.
    Fraser HM, Sandow J, Seidel H, von Rechenberg W.
    Acta Endocrinol (Copenh); 1987 Aug; 115(4):521-7. PubMed ID: 3115020
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.